Join the Jakafi group to help and get support from people like you.
Jakafi News
Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis
THURSDAY, March 27, 2025 – Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK...
Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Jakafi is approved for treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older Today’s approval marks the fourth F...
FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--May 24, 2019-- Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of...
FDA Approves Jakafi (ruxolitinib) for Polycythemia Vera
December 4, 2014 – The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is...